Description:

Individuals undergoing interferon therapy may develop neutralizing antibodies (NABs) that bind to the interferon and inhibit or reduce its therapeutic benefit.

The NAbFeron test has been investigated in the detection of neutralizing antibodies to interferon beta 1A or interferon beta 1B in individuals with multiple sclerosis and hepatitis C.
NEUTRALIZING ANTIBODY TESTS FOR INTERFERON (cont.)

Criteria:

- NAbFeron antibody testing for detection of antibodies to interferon beta is considered experimental or investigational based upon:
  1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and
  2. Insufficient evidence to support improvement of the net health outcome, and
  3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and
  4. Insufficient evidence to support improvement outside the investigational setting.

Resources: